Zimbabwe has rejected a major American health deal valued at $367m (272 million pounds) spanning five years because of the United States' insistence on sensitive biological samples.
The decision was revealed after a official document dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesperson later clarified that the US was requesting genetic material for research and profit but refused to guarantee the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more dialogue to secure a agreement agreeable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were filed about the security of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government deals to boost openness and responsibility.
According to statements, Sixteen African countries have to date signed similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the end products would be accessible to our citizens should a new pandemic arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were undermining structures previously set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This mechanism is intended to guarantee that when a country provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent co-operation might be designed in a manner that respects the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body expressed it acknowledged the official position, but suggested that talks must proceed given that a large portion of the nation's Aids initiatives were funded by international support.
"If technical issues arise, such as those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group added.
The situation emphasises the continuing tensions between receiving vital foreign assistance and safeguarding national sovereignty in an ever more interconnected world.